Study Detail

COVAC 1

A first-in-human clinical trial in healthy young and elderly adults to assess the safety, immunogenicity and exploratory evaluation of efficacy of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative

Status: Open

Type: Interventional

Funder: NIHR/UKRI

Sponsor: Imperial College London

CI: Katrina Pollack

IRAS-Number: 279315

CPMS-ID: 46068

Approval Date: 20 May 2020

Back to listing